Rare Cancer News & Clinical Trials » Trial

Permalink for 'Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma'

Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Posted: May 15th, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma, Intrahepatic
Intervention: Drug: combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
Sponsor: Shanghai Zhongshan Hospital
Recruiting

Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer

Posted: May 9th, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: nab-paclitaxel
Sponsor: Istituto Clinico Humanitas
Recruiting

Permalink for 'Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer'

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Posted: May 8th, 2019, 2:00pm GMT

Conditions: Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Radiation: External Beam Radiation Therapy; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting

Treatment of Advanced Intrahepatic Cholangiocarcinoma

Posted: May 7th, 2019, 2:00pm GMT

Condition: ICC
Interventions: Drug: Levamisole Hydrochloride; Drug: Anlotinib Hydrochloride Capsules
Sponsors: The First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Xinjiang Medical University; Luoyang Central Hospital; Nanyang Central Hospital; Anyang Tumor Hospital; Third People's Hospital of Jiaozuo; Sanmenxia Central Hospital; pinmei Group General Hospital
Recruiting

Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer

Posted: May 6th, 2019, 2:00pm GMT

Condition: Biliary Tract Cancer
Interventions: Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell); Drug: Pembrolizumab Injection [Keytruda]
Sponsor: SMT bio Co., Ltd.
Not yet recruiting

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Posted: April 9th, 2019, 2:00pm GMT

Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic
Interventions: Drug: TC-210 T Cells; Drug: fludarabine; Drug: cyclophosphamide; Biological: anti-PD1
Sponsor: TCR2 Therapeutics
Recruiting

Combination of Radiotherapy With Anti PD-1/PD-L1 Antibodies for Unresectable ICC

Posted: April 2nd, 2019, 2:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma; Radiotherapy; Immunotherapy
Interventions: Combination Product: SBRT+anti-PD-1; Drug: Gemcitabine+cisplatin
Sponsor: Sun Yat-sen University
Not yet recruiting

Permalink for 'The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)'

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Posted: April 1st, 2019, 2:00pm GMT

Conditions: Cancer, All Types; Cancer of Liver; Cancer of Stomach; Cancer of Head and Neck; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Colon; Cancer Skin; Cancer of Cervix; Cancer, Metastatic; Cancer of Larynx; Cancer of Neck; Cancer of Lung; Cancer of Brain and Nervous System; Cancer of Vulva, Disseminated; Cancer of Pancreas; Sarcoma; GIST; Small-cell Lung Cancer; Adenocarcinoma Lung; Cancer of Prostate; Cancer, Advanced; Adrenal Cancer; Testicular Cancer; Uterine Cancer; Bronchoalveolar Cell Lung Cancer; Cancer Unknown Primary; Glioblastoma Multiforme; Oligodendroglioma; Breast Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Cholangiocarcinoma; Squamous Cell Carcinoma; Transitional Cell Carcinoma; Cancer, Other; Cancer, Anal; Melanoma; Cancer, Bile Duct; Cancer, Bladder; Cancer Cords Vocal; Cancers Cell Neuroendocrine; Cancer Differentiated Poorly; Cancer, Anaplastic Thyroid
Intervention:
Sponsors: SpeciCare; Dana-Farber Cancer Institute; Kalispell Regional Medical Center; Georgia Institute of Technology; Ontario Institute for Cancer Research; SEngine Precision Medicine; Helomics
Recruiting

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Posted: March 29th, 2019, 2:00pm GMT

Conditions: Liver Neoplasm Malignant Primary; Cholangiocarcinoma; Combinational Immunotherapy; Biomarker
Intervention: Drug: Lenvatinib plus Pembrolizumab
Sponsor: Peking Union Medical College Hospital
Not yet recruiting

Olaparib and Ceralasertib in Treating Patients With IDH Mutant Cholangiocarcinoma or Solid Tumors

Posted: March 18th, 2019, 2:00pm GMT

Conditions: IDH1 Gene Mutation; IDH2 Gene Mutation; Malignant Solid Neoplasm; Progressive Disease; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Drug: Ceralasertib; Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Posted: March 13th, 2019, 2:00pm GMT

Conditions: Solid Tumor; Colon Cancer; Cholangiocarcinoma; Bladder Cancer; Ovarian Cancer; Gastric Cancer; Palpable Subcutaneous Malignant Lesions
Interventions: Biological: TRK-950; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Gemcitabine; Drug: Cisplatin; Drug: Carboplatin; Biological: Ramucirumab; Drug: Paclitaxel; Biological: Nivolumab; Biological: Pembrolizumab; Drug: Imiquimod Cream
Sponsor: Toray Industries, Inc
Recruiting

Toripalimab or Placebo as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Posted: March 8th, 2019, 3:00pm GMT

Condition: Epatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Intervention: Biological: TORIPALIMAB INJECTION(JS001 )
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting

Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images

Posted: February 25th, 2019, 3:00pm GMT

Conditions: Gallstone; Cholangitis; Cholangiocarcinoma; Pancreatitis; Pancreatic Ductal Adenocarcinoma
Intervention: Other: ultra-rapid acquisition of bile ducts images
Sponsor: IHU Strasbourg
Recruiting

Permalink for 'M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)'

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Posted: February 7th, 2019, 3:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting

TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers

Posted: February 4th, 2019, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Metastatic Castration Resistant Prostate Cancer; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple-Negative Breast Cancer; Urothelial Carcinoma; Cholangiocarcinoma; GastroEsophageal Cancer; Pancreatic Cancer; Sarcoma
Interventions: Drug: Part 1 TPST-1120; Drug: Part 2a TPST-1120 + nivolumab; Drug: Part 2b TPST-1120 + docetaxel; Drug: Part 2c TPST-1120 + cetuximab; Drug: Part 3 TPST-1120; Drug: Part 4a TPST-1120 + nivolumab; Drug: Part 4b TPST-1120 + docetaxel; Drug: Part 4c TPST-1120 + cetuximab
Sponsor: Tempest Therapeutics
Recruiting

Clinical Trial of Autologous Tcm Immunotherapy in ICC

Posted: January 29th, 2019, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Biological: autologous Tcm cellular immunotherapy
Sponsors: Newish Technology (Beijing) Co., Ltd.; Peking Union Medical College Hospital
Not yet recruiting

A Phase 1 Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Posted: January 29th, 2019, 3:00pm GMT

Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting

Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer

Posted: January 28th, 2019, 3:00pm GMT

Conditions: Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Unresectable Esophageal Carcinoma; Unresectable Pancreatic Carcinoma
Intervention: Dietary Supplement: Zinc
Sponsor: Emory University
Recruiting

Permalink for 'Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers'

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Posted: January 14th, 2019, 3:00pm GMT

Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Not yet recruiting

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Posted: January 11th, 2019, 3:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: Lenvatinib
Sponsor: Sun Yat-sen University
Recruiting

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

Posted: January 11th, 2019, 3:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms
Intervention: Biological: Tumor Infiltrating Lymphocytes (TIL)
Sponsor: Udai Kammula
Recruiting

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Posted: December 20th, 2018, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases
Intervention: Drug: MIV-818
Sponsor: Medivir
Recruiting

Phase 3 Study of BJG398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Posted: December 12th, 2018, 3:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Interventions: Drug: BGJ398; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: QED Therapeutics, Inc.
Recruiting

Trial of IRE in Cholangiocarcinoma

Posted: December 7th, 2018, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Device: IRE Device
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting

Permalink for 'Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers'

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Posted: December 7th, 2018, 3:00pm GMT

Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

Posted: December 5th, 2018, 3:00pm GMT

Condition: Primary Sclerosing Cholangitis (PSC)
Intervention: Device: SpyGlass DS I - II
Sponsor: Boston Scientific Corporation
Recruiting

A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors

Posted: November 8th, 2018, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer
Intervention: Drug: ZSP1241
Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Recruiting

Permalink for 'A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma'

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Posted: October 3rd, 2018, 2:00pm GMT

Conditions: Colorectal Cancer; Cholangiocarcinoma
Interventions: Device: Medtronic pump and Codman catheter; Drug: Floxuridine (FUDR); Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Irinotecan (CPT-11); Drug: Fluorouracil; Drug: Anti-EGFR (Panitumumab or Cetuximab)
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting

A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Posted: September 26th, 2018, 2:00pm GMT

Conditions: Cohort 1a and 1b: Glioma; Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations
Interventions: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin
Sponsor: Forma Therapeutics, Inc.
Recruiting

Permalink for 'A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)'

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

Posted: September 3rd, 2018, 2:00pm GMT

Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting

Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members

Posted: August 2nd, 2018, 2:00pm GMT

Condition: Gastrointestinal Cancer
Interventions: Other: Surgeon-palliative care team co management; Other: Surgeon team alone management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Recruiting

Prospective Surveillance for Very Early Hepatocellular Carcinoma

Posted: July 17th, 2018, 2:00pm GMT

Condition: Carcinoma, Hepatocellular
Intervention:
Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting

Ph1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors

Posted: July 11th, 2018, 2:00pm GMT

Condition: Solid Tumor
Intervention: Drug: EOC317
Sponsor: EddingPharm Oncology Co., LTD.
Recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Posted: July 9th, 2018, 2:00pm GMT

Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Posted: March 2nd, 2018, 3:00pm GMT

Conditions: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer
Intervention: Other: Clinical Trial Matching
Sponsor: Massive Bio, Inc.
Recruiting

Fluorescence QRH-882260 Peptide Imaging in the Bile Duct

Posted: February 19th, 2018, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: QRH-882260 Heptapeptide
Sponsors: D. Kim Turgeon, MD; University of Washington
Not yet recruiting

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Posted: February 6th, 2018, 3:00pm GMT

Conditions: Breast Cancer; Colorectal Cancer; Cholangiocellular Carcinoma; Sarcoma; Desmoid Tumour; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Posted: January 24th, 2018, 3:00pm GMT

Conditions: Liver Cancer; Liver Metastases
Intervention: Radiation: SBRT
Sponsor: Centre Oscar Lambret
Recruiting

A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma

Posted: December 19th, 2017, 3:00pm GMT

Conditions: Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Perihilar; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic
Intervention: Drug: ABC294640
Sponsor: RedHill Biopharma Limited
Recruiting

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Posted: November 13th, 2017, 3:00pm GMT

Conditions: Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer
Intervention: Drug: Abemaciclib
Sponsors: Jules Bordet Institute; Eli Lilly and Company
Recruiting

A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Posted: November 6th, 2017, 3:00pm GMT

Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Other Solid Tumors; Diffuse Large B-cell Lymphoma (DLBCL); Mantle Cell Lymphoma; Indolent B-cell Lymphomas; Non-Hodgkin Lymphoma
Interventions: Drug: CDX-1140; Drug: CDX-301
Sponsor: Celldex Therapeutics
Recruiting

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Posted: August 22nd, 2017, 2:00pm GMT

Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting

Permalink for 'A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma'

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Posted: August 15th, 2017, 2:00pm GMT

Conditions: Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer; Cholangiocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: Entinostat; Drug: Nivolumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Bristol-Myers Squibb
Recruiting

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

Posted: July 12th, 2017, 2:00pm GMT

Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Melanoma; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Skin Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Intestinal Neoplasms; Thyroid Cancer; GIST; Malignant Peripheral Nerve Sheath Tumors; Breast Secretory Carcinoma; Uterine Neoplasms; Fibrosarcoma; Infantile Fibrosarcoma; Congenital Mesoblastic Nephroma; Central Nervous System Neoplasms
Intervention: Drug: LOXO-195
Sponsors: Loxo Oncology, Inc.; Bayer
Recruiting

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

Posted: June 7th, 2017, 2:00pm GMT

Conditions: Autoimmune Liver Disease; Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Intervention:
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Posted: May 11th, 2017, 2:00pm GMT

Conditions: Solid Tumor, Adult; Breast Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Ovarian Cancer; Endometrial Cancer; Head and Neck Cancer; Cholangiocarcinoma
Intervention: Drug: CX-2009
Sponsor: CytomX Therapeutics
Recruiting

Permalink for 'An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies'

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Posted: May 9th, 2017, 2:00pm GMT

Conditions: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Solid Tumors
Intervention: Drug: INCB062079
Sponsor: Incyte Corporation
Recruiting

Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer

Posted: May 3rd, 2017, 2:00pm GMT

Conditions: Colon Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Pancreatic Carcinoma
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Other: Laboratory Procedure
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting

Permalink for 'Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)'

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Posted: April 13th, 2017, 2:00pm GMT

Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting

Permalink for 'A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors'

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Posted: March 7th, 2017, 3:00pm GMT

Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

Posted: February 7th, 2017, 3:00pm GMT

Conditions: Adenocarcinoma Metastatic; Biliary Tract Cancer; Adenocarcinoma of the Biliary Tract; Adenocarinoma Locally Advanced; Non-Resectable Hepatocellular Carcinoma; Intrahepatic Bile Duct Carcinoma; Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Drug: Arm Cisplatin + Gemcitabine (Arm B)
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire, Baxalta); Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH
Recruiting

Permalink for 'Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies'

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Posted: February 6th, 2017, 3:00pm GMT

Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire)
Recruiting

A Study of ABBV-181 in Participants With Advanced Solid Tumors

Posted: December 22nd, 2016, 3:00pm GMT

Condition: Advanced Solid Tumors
Interventions: Drug: Rovalpituzumab Tesirine; Drug: ABBV-181
Sponsor: AbbVie
Recruiting

A Study of TRK-950 in Patients With Advanced Solid Tumors

Posted: December 13th, 2016, 3:00pm GMT

Conditions: Locally Advanced or Metastatic Solid Carcinomas; Colon Cancer; Cholangiocarcinoma
Intervention: Biological: TRK-950
Sponsor: Toray Industries, Inc
Recruiting

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Posted: October 5th, 2016, 2:00pm GMT

Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting

Permalink for 'Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma'

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Posted: July 15th, 2016, 2:00pm GMT

Conditions: Advanced Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Hepatocellular Carcinoma; Liver Cancer; Liver Neoplasms; Hepatic Cancer; Hepatic Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Intervention: Drug: H3B-6527
Sponsors: H3 Biomedicine Inc.; Eisai Inc.
Recruiting

Permalink for 'A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)'

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Posted: July 4th, 2016, 2:00pm GMT

Conditions: Biliary Tract Neoplasms; Liver Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Procedure: TACE; Procedure: RFA; Procedure: Cryoablation
Sponsor: National Cancer Institute (NCI)
Recruiting

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Posted: May 2nd, 2016, 2:00pm GMT

Conditions: Cholangiocarcinoma; Colorectal Adenocarcinoma; Esophageal Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Gastric Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Biological: Adoptive Immunotherapy; Biological: Aldesleukin; Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting

Quality of Life in Patients With Primary Sclerosing Cholangitis

Posted: March 18th, 2016, 2:00pm GMT

Condition: Primary Sclerosing Cholangitis
Intervention: Other: quality of life survey
Sponsor: Duke University
Recruiting

Permalink for 'A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho'

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho

Posted: March 4th, 2016, 3:00pm GMT

Condition: Neoplasm
Intervention: Drug: Erdafitinib
Sponsor: Janssen Research & Development, LLC
Recruiting

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Posted: February 19th, 2016, 3:00pm GMT

Condition: Localized Non-Resectable Adult Liver Carcinoma
Intervention: Other: Yttrium-90 Resin Microspheres
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting

Permalink for 'A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction'

A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction

Posted: January 20th, 2016, 3:00pm GMT

Conditions: Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; HCC; AOV Cancer
Interventions: Procedure: side by side; Procedure: stent in stent
Sponsor: Yonsei University
Recruiting

Permalink for 'Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study'

Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study

Posted: January 5th, 2016, 3:00pm GMT

Condition: Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Interventions: Device: Radiofrequency ablation with stenting; Device: stenting
Sponsor: Yonsei University
Recruiting

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Posted: December 16th, 2015, 3:00pm GMT

Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting

Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function

Posted: December 10th, 2015, 3:00pm GMT

Conditions: Cholangiocarcinoma; Cirrhosis; Hepatocellular Carcinoma; Metastatic Malignant Neoplasm in the Liver
Interventions: Other: Laboratory Biomarker Analysis; Procedure: Magnetic Resonance Imaging; Radiation: Radiation Therapy; Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting

Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

Posted: October 15th, 2015, 2:00pm GMT

Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas
Intervention: Drug: Larotrectinib LOXO-101
Sponsors: Bayer; Loxo Oncology, Inc.
Recruiting

OLAParib COmbinations

Posted: October 15th, 2015, 2:00pm GMT

Condition: Cancer
Interventions: Drug: AZD2281; Drug: AZD5363; Drug: AZD1775; Drug: AZD6738
Sponsors: Joseph Paul Eder; Dana-Farber Cancer Institute; Vanderbilt-Ingram Cancer Center; The Cleveland Clinic
Recruiting

Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)

Posted: August 24th, 2015, 2:00pm GMT

Condition: Pancreatic Neoplasms
Intervention: Other: blood and bile
Sponsor: Florida Hospital
Recruiting

Permalink for 'Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery'

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Posted: August 11th, 2015, 2:00pm GMT

Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Ramucirumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

Posted: May 27th, 2015, 2:00pm GMT

Condition: Solid Tumor
Intervention: Biological: FF21101
Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
Recruiting

Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)

Posted: March 19th, 2015, 2:00pm GMT

Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
Interventions: Drug: Pemigatinib; Drug: Gemcitabine + Cisplatin; Drug: Pembrolizumab; Drug: Docetaxel; Drug: Trastuzumab; Drug: INCMGA00012
Sponsor: Incyte Corporation
Recruiting

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L

Posted: September 5th, 2014, 2:00pm GMT

Conditions: Hepatocellular Carcinoma; HCC; Liver Cancer
Interventions: Biological: hepcortespenlisimut-L; Biological: Placebo
Sponsor: Immunitor LLC
Recruiting

Permalink for 'Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer'

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Posted: June 23rd, 2014, 2:00pm GMT

Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Deutsche Krebshilfe e.V., Bonn (Germany); medac GmbH; Cancer Research UK; Australasian Gastro-Intestinal Trials Group; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG)
Recruiting

Treatment for Bile Duct Cancer in the Liver

Posted: June 19th, 2014, 2:00pm GMT

Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
Sponsor: Chinese University of Hong Kong
Recruiting

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Posted: May 30th, 2014, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Intervention: Drug: BGJ398 (infigratinib)
Sponsor: QED Therapeutics, Inc.
Recruiting

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Posted: May 1st, 2014, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Drug: CX-4945; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Senhwa Biosciences, Inc.
Recruiting

International Registry on Cholangiocarcinoma Treatment

Posted: August 12th, 2013, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: Doxorubicin
Sponsor: International Group of Endovascular Oncology
Recruiting

Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

Trial - Cholangiocarcinoma (77 unread)

Posted: May 15th, 2019, 2:00pm GMT

Posted: May 9th, 2019, 2:00pm GMT

Posted: May 8th, 2019, 2:00pm GMT

Posted: May 7th, 2019, 2:00pm GMT

Posted: May 6th, 2019, 2:00pm GMT

Posted: April 9th, 2019, 2:00pm GMT

Posted: April 2nd, 2019, 2:00pm GMT

Posted: April 1st, 2019, 2:00pm GMT

Posted: March 29th, 2019, 2:00pm GMT

Posted: March 18th, 2019, 2:00pm GMT

Posted: March 13th, 2019, 2:00pm GMT

Posted: March 8th, 2019, 3:00pm GMT

Posted: February 25th, 2019, 3:00pm GMT

Posted: February 7th, 2019, 3:00pm GMT

Posted: February 4th, 2019, 3:00pm GMT

Posted: January 29th, 2019, 3:00pm GMT

Posted: January 29th, 2019, 3:00pm GMT

Posted: January 28th, 2019, 3:00pm GMT

Posted: January 14th, 2019, 3:00pm GMT

Posted: January 11th, 2019, 3:00pm GMT

Posted: January 11th, 2019, 3:00pm GMT

Posted: December 20th, 2018, 3:00pm GMT

Posted: December 12th, 2018, 3:00pm GMT

Posted: December 7th, 2018, 3:00pm GMT

Posted: December 7th, 2018, 3:00pm GMT

Posted: December 5th, 2018, 3:00pm GMT

Posted: November 8th, 2018, 3:00pm GMT

Posted: October 3rd, 2018, 2:00pm GMT

Posted: September 26th, 2018, 2:00pm GMT

Posted: September 3rd, 2018, 2:00pm GMT

Posted: August 2nd, 2018, 2:00pm GMT

Posted: July 17th, 2018, 2:00pm GMT

Posted: July 11th, 2018, 2:00pm GMT

Posted: July 9th, 2018, 2:00pm GMT

Posted: March 2nd, 2018, 3:00pm GMT

Posted: February 19th, 2018, 3:00pm GMT

Posted: February 6th, 2018, 3:00pm GMT

Posted: January 24th, 2018, 3:00pm GMT

Posted: December 19th, 2017, 3:00pm GMT

Posted: November 13th, 2017, 3:00pm GMT

Posted: November 6th, 2017, 3:00pm GMT

Posted: August 22nd, 2017, 2:00pm GMT

Posted: August 15th, 2017, 2:00pm GMT

Posted: July 12th, 2017, 2:00pm GMT

Posted: June 7th, 2017, 2:00pm GMT

Posted: May 11th, 2017, 2:00pm GMT

Posted: May 9th, 2017, 2:00pm GMT

Posted: May 3rd, 2017, 2:00pm GMT

Posted: April 13th, 2017, 2:00pm GMT

Posted: March 7th, 2017, 3:00pm GMT

Posted: February 7th, 2017, 3:00pm GMT

Posted: February 6th, 2017, 3:00pm GMT

Posted: December 22nd, 2016, 3:00pm GMT

Posted: December 13th, 2016, 3:00pm GMT

Posted: October 5th, 2016, 2:00pm GMT

Posted: July 15th, 2016, 2:00pm GMT

Posted: July 4th, 2016, 2:00pm GMT

Posted: May 2nd, 2016, 2:00pm GMT

Posted: March 18th, 2016, 2:00pm GMT

Posted: March 4th, 2016, 3:00pm GMT

Posted: February 19th, 2016, 3:00pm GMT

Posted: January 20th, 2016, 3:00pm GMT

Posted: January 5th, 2016, 3:00pm GMT

Posted: December 16th, 2015, 3:00pm GMT

Posted: December 10th, 2015, 3:00pm GMT

Posted: October 15th, 2015, 2:00pm GMT

Posted: October 15th, 2015, 2:00pm GMT

Posted: August 24th, 2015, 2:00pm GMT

Posted: August 11th, 2015, 2:00pm GMT

Posted: May 27th, 2015, 2:00pm GMT

Posted: March 19th, 2015, 2:00pm GMT

Posted: September 5th, 2014, 2:00pm GMT

Posted: June 23rd, 2014, 2:00pm GMT